Outcomes of Surgical Treatment for Graves’ Disease: A Single-Center Experience of 216 Cases
Open Access
- 7 February 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (4) , 1308
Abstract
Background: The role of surgery in the treatment of Graves’ disease (GD) needs to be revisited. The aims of the present retrospective study were to evaluate the outcomes of the current surgical strategy as a definitive treatment of GD at our center and to explore the clinical association between GD and thyroid cancer. Methods: A patient cohort of 216 cases from 2013 to 2020 was involved in this retrospective study. The data of the clinical characteristics and follow-up results were collected and analyzed. Results: There were 182 female and 34 male patients. The mean age was 43.9 ± 15.0 years old. The mean duration of GD reached 72.2 ± 92.7 months. Of the 216 cases, 211 had been treated with antithyroid drugs (ATDs) and hyperthyroidism had been completely controlled in 198 cases. A total (75%) or near-total (23.6%) thyroidectomy was performed. Intraoperative neural monitoring (IONM) was applied to 37 patients. The failure of ATD therapy (52.3%) was the most common surgical indication, followed by suspicion of a malignant nodule (45.8%). A total of 24 (11.1%) patients had hoarseness after the operation and 15 (6.9%) patients had transient vocal cord paralysis; 3 (1.4%) had this problem permanently. No bilateral RLN paralysis occurred. A total of 45 patients had hypoparathyroidism and 42 of them recovered within 6 months. Sex showed a correlation with hypoparathyroidism through a univariate analysis. A total of 2 (0.9%) patients underwent a reoperation because of hematomas. A total of 104 (48.1%) cases were diagnosed as thyroid cancer. In most cases (72.1%), the malignant nodules were microcarcinomas. A total of 38 patients had a central compartment node metastasis. A lateral lymph node metastasis occurred in 10 patients. Thyroid carcinomas were incidentally discovered in the specimens of 7 cases. The patients with concomitant thyroid cancer had a significant difference in body mass index, duration of GD, gland size, thyrotropin receptor antibodies and nodule(s) detected. Conclusion: Surgical treatments for GD were effective, with a relatively low incidence of complications at this high-volume center. Concomitant thyroid cancer is one of the most important surgical indications for GD patients. Careful ultrasonic screening is necessary to exclude the presence of malignancies and to determine the therapeutic plan.Keywords
This publication has 40 references indexed in Scilit:
- A 2013 European survey of clinical practice patterns in the management of Graves' diseaseClinical Endocrinology, 2015
- Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemiaBritish Journal of Surgery, 2014
- Cancer Risk in Patients with Graves' Disease: A Nationwide Cohort StudyThyroid®, 2013
- Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves’ diseases: a meta‐analysis of randomized clinical trialsClinical Endocrinology, 2013
- Randomized clinical trial of bilateral subtotal thyroidectomy versus total thyroidectomy for Graves' disease with a 5-year follow-up11British Journal of Surgery, 2012
- Electrophysiologic recurrent laryngeal nerve monitoring during thyroid and parathyroid surgery: International standards guideline statementThe Laryngoscope, 2010
- Cancer risk in patients hospitalised for Graves’ disease: a population-based cohort study in SwedenBritish Journal of Cancer, 2010
- Optimal Depth of NIM EMG Endotracheal Tube for Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerve During ThyroidectomyWorld Journal of Surgery, 2008
- Prognosis of small thyroid cancer in patients with Graves' diseaseBritish Journal of Surgery, 2006
- Graves' Disease with Moderate–Severe Endocrine Ophthalmopathy–Long Term Results of a Prospective, Randomized Study of Total or Subtotal Thyroid ResectionThyroid®, 2005